Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in: Breast Cancer Research and Treatment 2/2007

01.12.2007 | Preclinical Type

A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models

verfasst von: Hiroyuki Ishida, Taisuke Nakata, Masayo Suzuki, Yukimasa Shiotsu, Hideyuki Tanaka, Natsuko Sato, Yoko Terasaki, Miho Takebayashi, Hideharu Anazawa, Chikara Murakata, Pui-Kai Li, Takashi Kuwabara, Shiro Akinaga

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

We screened a series of 17β-(N-alkylcarbamoyl)-estra-1,3,5(10)trine-3-O-sulfamate derivatives, and describe here a potent and selective steroid sulfatase (STS) inhibitor with antitumor effects in breast cancer models in vitro and in vivo. In biochemical assays using crude enzymes isolated from recombinant Chinese hamster ovary cells expressing human arylsulfatses (ARSs), one of the best compounds, KW-2581, inhibited STS activity with an IC50 of 4.0 nM, while > 1000-fold higher concentrations were required to inhibit the other ARSs. The failure to stimulate the growth of MCF-7 human breast cancer cells as well as in uteri in ovariectomized rats indicated the lack of estrogenicity of this compound. In MCF-7 cells transfected with the STS gene, termed MCS-2 cells, KW-2581 inhibited the growth of cells stimulated by estrone sulfate (E1S) but also 5-androstene-3β, 17β-diol 3-sulfate (ADIOLS) and dehydroepiandrostenedione 3-sulfate. We found that oral administration of KW-2581 inhibited both E1S- and ADIOLS-stimulated growth of MCS-2 cells in a mouse hollow fiber model. In a nitrosomethylurea-induced rat mammary tumor model, KW-2581 induced regression of E1S-stimulated tumor growth as effectively as tamoxifen or another STS inhibitor, 667 Coumate. Dose-response studies in the same rat model demonstrated that more than 90% inhibition of STS activity in tumors was necessary to induce tumor shrinkage. STS activity in tumors has well correlated with that in leukocytes, suggesting that STS activity in leukocytes could be used as an easily detectable pharmacodynamic marker. These findings demonstrate that KW-2581 is a candidate for development as a therapeutic agent for the treatment of hormone receptors-positive breast cancer.
Literatur
1.
Parenti G, Meroni G, Ballabio A (1997) The sulfatase gene family. Curr Opin Genet Dev 7:386–391CrossRefPubMed
2.
Dibbelt L, Kuss E: (1991) Human placental sterylsulfatase interaction of the isolated enzyme with substrates, products, transition-state analogues, amino-acid modifiers and anion transport inhibitors. Biol Chem Hoppe Seyler 372:173–185PubMed
3.
Mehl E, Jatzkewitz H (1968) Cerebroside 3-sulfate as a physiological substrate of arylsulfatase A. Biochim Biophys Acta 151:619–627PubMed
4.
Matalon R, Arbogast B, Dorfman A (1974) Deficiency of chondroitin sulfate N-acetylgalactosamine 4-sulfate sulfatase in Maroteaux-Lamy syndrome. Biochem Biophys Res Commun 61:1450–1457CrossRefPubMed
5.
O’Brien JF, Cantz M, Spranger J (1974) Maroteaux-Lamy disease (mucopolysaccharidosis VI), subtype A: deficiency of a N-acetylgalactosamine-4-sulfatase. Biochem Biophys Res Commun 60:1170–1177CrossRefPubMed
6.
Chang PL, Mueller OT, Lafrenie RM, Varey PA, Rosa NE, Davidson RG, Henry WM, Shows TB (1990) The human arylsulfatase-C isoenzymes: two distinct genes that escape from X inactivation. Am J Hum Genet 46:729–737PubMed
7.
Franco B, Meroni G, Parenti G, Levilliers J, Bernard L, Gebbia M, Cox L, Maroteaux P, Sheffield L, Rappold GA, Andria G, Petit C, Ballabio A (1995) A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. Cell 81:15–25CrossRefPubMed
8.
Puca AA, Zollo M, Repetto M, Andolfi G, Guffanti A, Simon G, Ballabio A, Franco B (1997) Identification by shotgun sequencing, genomic organization, and functional analysis of a fourth arylsulfatase gene (ARSF) from the Xp22.3 region. Genomics 42:192–199CrossRefPubMed
9.
Fluharty AL, Fluharty CB, Bohne W, von Figura K, Gieselmann V (1991) Two new arylsulfatase A (ARSA) mutations in a juvenile metachromatic leukodystrophy (MLD) patient. Am J Hum Genet 49:1340–1350PubMed
10.
Litjens T, Hopwood JJ (2001) Mucopolysaccharidosis type VI: structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat 18:282–295CrossRefPubMed
11.
Ballabio A, Parenti G, Tippett P, Mondello C, Di Maio S, Tenore A, Andria G (1986) X-linked ichthyosis, due to steroid sulphatase deficiency, associated with Kallmann syndrome (hypogonadotropic hypogonadism and anosmia): linkage relationships with Xg and cloned DNA sequences from the distal short arm of the X chromosome. Hum Genet 72:237–240CrossRefPubMed
12.
Hernandez-Martin A, Gonzalez-Sarmiento R, De Unamuno P (1999) X-linked ichthyosis: an update. Br J Dermatol 141:617–627CrossRefPubMed
13.
Zettersten E, Man MQ, Sato J, Denda M, Farrell A, Ghadially R, Williams ML, Feingold KR, Elias PM (1998) Recessive X-linked ichthyosis: role of cholesterol-sulfate accumulation in the barrier abnormality. J Invest Dermatol 111:784–790CrossRefPubMed
14.
Parenti G, Buttitta P, Meroni G, Franco B, Bernard L, Rizzolo MG, Brunetti-Pierri N, Ballabio A, Andria G (1997) X-linked recessive chondrodysplasia punctata due to a new point mutation of the ARSE gene. Am J Med Genet 73:139–143CrossRefPubMed
15.
Henderson IC, Canellos GP (1980) Cancer of the breast: the past decade. N Engl J Med 302:17–30PubMedCrossRef
16.
Suzuki T, Moriya T, Ishida T, Ohuchi N, Sasano H (2003) Intracrine mechanism of estrogen synthesis in breast cancer. Biomed Pharmacother 57:460–462CrossRefPubMed
17.
Miller WR, Dixon JM (2001) Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 79:93–102CrossRefPubMed
18.
MacIndoe JH (1988) The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. Endocrinology 123:1281–1287PubMedCrossRef
19.
Prost O, Turrel MO, Dahan N, Craveur C, Adessi GL (1984) Estrone and dehydroepiandrosterone sulfatase activities and plasma estrone sulfate levels in human breast carcinoma. Cancer Res 44:661–664PubMed
20.
Perel E, Daniilescu D, Kharlip L, Blackstein M, Killinger DW (1988) Steroid modulation of aromatase activity in human cultured breast carcinoma cells. J Steroid Biochem 29:393–399CrossRefPubMed
21.
Abul-Hajj YJ (1979) Relationship between estrogen receptors, 17 beta-hydroxysteroid dehydrogenase and estrogen content in human breast cancer. Steroids 34:217–225CrossRefPubMed
22.
Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC (1986) Aromatase, 17 β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 22:515–525CrossRefPubMed
23.
Poulin R, Labrie F (1986) Stimulation of cell proliferation and estrogenic response by adrenal C19Δ5 steroids in the ZR-75–1 human breast cancer cell line. Cancer Res 46:4933–4937PubMed
24.
Bonney CB, Scanlon MJ, Jones DL, Beranek PA, Reed MJ, James VHT (1984) The interrelationship between plasma 5-ene adrenal androgens in normal women. J Steroid Biochem 20:1353–1355CrossRefPubMed
25.
Poortman J, Andriesse R, Agema A, Donker GH, Schwarz F, Thijssen JHH (1980) Adrenal androgen secretion and metabolism in postmenopausal women. In: Genazzani AR, Thijssen JHH, Siiteri PK (eds) Adrenal androgens. Raven Press, New York, pp 219–240
26.
Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K, Harada N (1999) Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res 59:377–381PubMed
27.
Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Taguchi T, Tamaki Y, Noguchi S (2003) High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 9:2288–2293PubMed
28.
Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S, Hirakawa H, Kimura M, Sasano H (2003) Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 63:2762–2770PubMed
29.
Boeddinghaus MI, Dowsett M (2001) Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 79:85–91CrossRefPubMed
30.
Saji S, Toi M (2002) Aromatase inhibitors and other novel agents in breast cancer treatment. Expert Opin Emerging Drugs 7:301–317CrossRef
31.
Nussbaumer P, Billich A (2003) Steroid sulfatase inhibitors. Expert Opin Ther Patents 13:605–625CrossRef
32.
Ahmed S, Owen CP, James K, Sampson L, Patel CK (2002) Review of estrone sulfatase and its inhibitors – an important new target against hormone dependent breast cancer. Curr Med Chem 9:263–273PubMed
33.
Stanway SJ, Purohit A, Woo LW, Sufi S, Vigushin D, Ward R, Wilson RH, Stanczyk FZ, Dobbs N, Kulinskaya E, Elliott M, Potter BV, Reed MJ, Coombes RC (2006) Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 12:1585–1592CrossRefPubMed
34.
Ishida H, Nakata T, Sato N, Li PK, Kuwabara T, Akinaga S (2006) Inhibition of steroid sulfatase activity and cell proliferation in ZR-75-1 and BT-474 human breast cancer cells by KW-2581 in vitro and in vivo. Breast Cancer Res Treat DOI: 10.1007/s10549-006-9404-8
35.
Fluharty AL, Edmond J (1978) Arylsulfatases A and B from human liver. Methods Enzymol 50:537–547PubMedCrossRef
36.
Simard JP, Ameen M, Chang PL (1985) Biochemical characterization of arylsulfatase-C isozymes in human fibroblasts. Biochem Biophys Res Commun 128:1388–1394PubMedCrossRef
37.
Denizot F, Lang R (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89:271–277CrossRefPubMed
38.
Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR (1995) In vivo cultivation of tumor cells in hollow fibers. Life Sci 57:131–141CrossRefPubMed
39.
Alley MC, Pacula-Cox CM, Hursey ML, Rubinstein LR, Boyd MR (1991) Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture. Cancer Res 51:1247–1256PubMed
40.
Woo LWL, Purohit A, Malini B, Reed MJ, Potter BVL (2000) Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem Biol 7:773–791CrossRefPubMed
41.
James MR, Skaar TC, Lee RY, MacPherson A, Zwiebel JA, Ahluwalia BS, Ampy F, Clarke R (2001) Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. Endocrinology 142:1497–1505CrossRefPubMed
42.
Purohit A, Williams GJ, Roberts CJ, Potter BVL, Reed MJ (1995) In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int J Cancer 63:106–111CrossRefPubMed
43.
Purohit A, Woo LW, Potter BVL, Reed MJ (2000) In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. Cancer Res 60:3394–3396PubMed
44.
Schreiner EP, Wolff B, Winiski AP, Billich A (2003) 6-(2-adamantan-2-ylidene-hydroxybenzoxazole)-O-sulfamate: a potent non-steroidal irreversible inhibitor of human steroid sulfatase. Bioorg Med Chem Lett 13:4313–4316CrossRefPubMed
45.
Purohit A, Vernon KA, Hummelinck AE, Woo LW, Hejaz HA, Potter BV, Reed MJ (1998) The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J Steroid Biochem Mol Biol 64:269–275CrossRefPubMed
46.
Billich A, Nussbaumer P, Lehr P (2000) Stimulation of MCF-7 breast cancer cell proliferation by estrone sulfate and dehydroepiandrosterone sulfate: inhibition by novel non-steroidal steroid sulfatase inhibitors. J Steroid Biochem Mol Biol 73:225–235CrossRefPubMed
47.
Okada M, Nakagawa T, Iwashita S, Takegawa S, Fujii T, Koizumi N (2003) Development of novel steroid sulfatase inhibitors. I. Synthesis and biological evaluation of biphenyl-4-O-sulfamates. J Steroid Biochem Mol Biol 87:141–148CrossRefPubMed
48.
Shields-Botella J, Bonnet P, Duc I, Duranti E, Meschi S, Cardinali S, Prouheze P, Chaigneau AM, Duranti V, Gribaudo S, Riviere A, Mengual L, Carniato D, Cecchet L, Lafay J, Rondot B, Sandri J, Pascal JC, Delansorne R (2003) In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity. J Steroid Biochem Mol Biol 84:327–335CrossRefPubMed
49.
Peters RH, Chao WR, Sato B, Shigeno K, Zaveri NT, Tanabe M (2003) Steroidal oxathiazine inhibitors of estrone sulfatase. Steroids 68:97–110CrossRefPubMed
50.
Nakata T, Takashima S, Shiotsu Y, Murakata C, Ishida H, Akinaga S, Li PK, Sasano H, Suzuki T, Saeki T (2003) Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J Steroid Biochem Mol Biol 86:455–460CrossRefPubMed
51.
Dorgan JF, Stanczyk FZ, Longcope C, Stephenson HE Jr, Chang L, Miller R, Franz C, Falk RT, Kahle L (1997) Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 6:177–181PubMed
52.
Dikkeschei LD, Willemse PH, Wolthers BG, de Ruyter-Buitenhuis AW, Nagel GT (1993) Delta-5-androstenediol and its sulphate in serum and urine of normal adults and patients with endocrine diseases. Clin Endocrinol 39:475–482
53.
Rose DP, Noonan JJ (1981) Hormone dependence of rat mammary tumors induced by N-nitrosomethylurea. Eur J Cancer Clin Oncol 17:1357–1358CrossRefPubMed
54.
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) ATAC Trialists’ Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMed
55.
Brodie A, Jelovac D, Long BJ (2003) Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clin Cancer Res 9:455S-459SPubMed
Metadaten
Titel
A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models
verfasst von
Hiroyuki Ishida
Taisuke Nakata
Masayo Suzuki
Yukimasa Shiotsu
Hideyuki Tanaka
Natsuko Sato
Yoko Terasaki
Miho Takebayashi
Hideharu Anazawa
Chikara Murakata
Pui-Kai Li
Takashi Kuwabara
Shiro Akinaga
Publikationsdatum
01.12.2007
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2007
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9495-x

Weitere Artikel der Ausgabe 2/2007

Breast Cancer Research and Treatment 2/2007 Zur Ausgabe

Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors

Original Paper

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population

Epidemiology

Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis

Epidemiology

Alcohol metabolism, alcohol intake, and breast cancer risk: a sister-set analysis using the Breast Cancer Family Registry

Epidemiology

Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling

Epidemiology

Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise